Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Genomas Presents Drug-Specific Genetic Determinants Of Statin Safety And Efficacy At The XV International Symposium On Atherosclerosis
Genomas, a biomedical company advancing DNA-guided medicine and personalized healthcare, announced its participation at the prestigious XV International Symposium on Atherosclerosis, a meeting held triennially by the International Atherosclerosis Society. Gualberto Ruano, MD, PhD, President of Genomas, will present "Physiogenomic Contours of Statin Safety and Efficacy," a clinical study examining the differences in response to statin drugs based on individual gene variations.
generic viagra online
Polls Show Americans Struggling To Pay For Health Care
A new study reports that about one-fourth of Americans say they"ve struggled in the last 12 months to pay for health care, Reuters reports.
News of the day
European Food Safety Authority Completes First EU-wide Assessment Of Vitamin And Mineral s Used In Food Supplements
The European Food Safety Authority (EFSA) has completed the first comprehensive assessment of substances used as s of vitamins and minerals in food supplements which are currently sold in the European Union. EFSA has examined 533 applications since 2005, relating to 344 different substances. The assessments were based on scientific evidence provided by food supplement manufacturers to demonstrate the safety of these nutrient s and the extent to which they are absorbed in the body (i.e. their bioavailability).
Sexual Health

FDA Issues Advertising Guidelines On Product Risk Information

FDA on Tuesday posted on its Web site advertising guidelines for drugmakers and medical device manufacturers, offering suggestions on how to present risk information to health care professionals and consumers, the Wall Street Journal reports. Agency officials said the industry had asked for guidance on how to comply with its rules, which require a balanced presentation of a product"s risk and effectiveness. Exclusion or minimization of risk information is the most commonly cited violation each year in FDA-issued warnings or enforcement letters. The new guidelines include detailed information on how aspects such as font, types of contrast and white space in print materials can appropriately present risk information. According to the Journal, the 24-page document is not binding. FDA will accept public comments for 90 days prior to issuing final guidelines (Corbett Dooren, Wall Street Journal, 5/27). Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation. © 2009 Advisory Board Company and Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009